These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Preparation and preclinical pharmacological study on a novel bone imaging agent (99m)Tc-EMIDP. Lin J, Luo S, Chen C, Qiu L, Wang Y, Cheng W, Ye W, Xia Y. Appl Radiat Isot; 2010 Sep; 68(9):1616-22. PubMed ID: 20363146 [Abstract] [Full Text] [Related]
7. Synthesis and biological evaluation of novel (99m)Tc-labelled bisphosphonates as superior bone imaging agents. Qiu L, Cheng W, Lin J, Luo S, Xue L, Pan J. Molecules; 2011 Jul 25; 16(8):6165-78. PubMed ID: 21788926 [Abstract] [Full Text] [Related]
11. Development and Pharmacological Evaluation of New Bone-Targeted (99m)Tc-Radiolabeled Bisphosphonates. Makris G, Tseligka ED, Pirmettis I, Papadopoulos MS, Vizirianakis IS, Papagiannopoulou D. Mol Pharm; 2016 Jul 05; 13(7):2301-17. PubMed ID: 27170456 [Abstract] [Full Text] [Related]
12. Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. Ogawa K, Mukai T, Inoue Y, Ono M, Saji H. J Nucl Med; 2006 Dec 05; 47(12):2042-7. PubMed ID: 17138748 [Abstract] [Full Text] [Related]
13. Bone targeted new zoledronate derivative: design, synthesis, 99mTc-coupling, in-silico study and preclinical evaluation for promising osteosarcoma therapy. Fayez H, Selim AA. Int J Radiat Biol; 2022 May 11; ():1-9. PubMed ID: 35511480 [Abstract] [Full Text] [Related]
14. Animal studies of 99mTc-i-PIDP: a new bone imaging agent. Wang Y, Luo S, Lin J, Qiu L, Cheng W, Zhai H, Nan B, Ye W, Xia Y. Appl Radiat Isot; 2011 Sep 11; 69(9):1169-75. PubMed ID: 21507669 [Abstract] [Full Text] [Related]
15. Labeling, characterization, and in vivo localization of a new 90Y-based phosphonate chelate 2,3-dicarboxypropane-1,1-diphosphonic acid for the treatment of bone metastases: Comparison with 99mTc-DPD complex. Djokić DDj, Janković DLj, Nikolić NS. Bioorg Med Chem; 2008 Apr 15; 16(8):4457-65. PubMed ID: 18331797 [Abstract] [Full Text] [Related]
17. Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker. Chu T, Li R, Hu S, Liu X, Wang X. Nucl Med Biol; 2004 Feb 15; 31(2):199-203. PubMed ID: 15013485 [Abstract] [Full Text] [Related]
18. Synthesis and evaluation of a 99mTc tricarbonyl-labeled somatostatin receptor-targeting antagonist peptide for imaging of neuroendocrine tumors. Radford L, Gallazzi F, Watkinson L, Carmack T, Berendzen A, Lewis MR, Jurisson SS, Papagiannopoulou D, Hennkens HM. Nucl Med Biol; 2017 Apr 15; 47():4-9. PubMed ID: 28043006 [Abstract] [Full Text] [Related]
19. Biological evaluation of a technetium-99m-labeled integrated tropane-BAT and its piperidine congener as potential dopamine transporter imaging agents. Kieffer DM, Vanbilloen HP, Cleynhens BJ, Terwinghe CY, Mortelmans L, Bormans GM, Verbruggen AM. Nucl Med Biol; 2006 Jan 15; 33(1):125-33. PubMed ID: 16459268 [Abstract] [Full Text] [Related]
20. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals. Bevan JA, Tofe AJ, Benedict JJ, Francis MD, Barnett BL. J Nucl Med; 1980 Oct 15; 21(10):961-6. PubMed ID: 6252298 [Abstract] [Full Text] [Related] Page: [Next] [New Search]